Find Articles in:
All
Business
Reference
Technology
News
Lifestyle

Fluticasone cream generic gains tentative approval

Journal of Drugs in Dermatology, Sept-Oct, 2004

The FDA granted Atrix Laboratories tentative approval of the Abbreviated New Drug Application to market fluticasone propionate cream 0.05%. The new generic product is therapeutically bioequivalent to Cutivate, which is marketed by GlaxoSmithKline. The patent for Cutivate cream expired on May 14. 2004.

COPYRIGHT 2004 Journal of Drugs in Dermatology, Inc.
COPYRIGHT 2008 Gale, Cengage Learning
 

BNET TalkbackShare your ideas and expertise on this topic

The following tags are supported in BNET comments:
<b></b> <i></i> <u></u> <pre></pre>

Leave a Reply

  1. You are currently a guest | Login?
advertisement
Go
advertisement
  • Click Here
  • Click Here
advertisement

Content provided in partnership with Thompson Gale